Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹2,151 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Narayana Hrudayalaya reported a strong Q3 FY26, driven by India business margin expansion of 150-200 bps YoY from payor mix optimization, robotic surgeries, and technology infusion. Bangalore cluster led growth, while North faced softness due to scheme payer caps and competition. Cayman insurance losses widened despite revenue growth, but management expects underwriting focus from Q4. UK acquisition (Practice Plus) contributed 2 months, with EBITDA margins at 8.5-9% pre-IFRS; Birmingham hospital losses are expected to narrow within 4 quarters. India like-to-like growth is sustainable until new hospitals (900 beds in Bangalore, Kolkata health city) come online. Key risk: increased competition in Gurgaon and North Bangalore may pressure occupancy and realizations.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects double-digit revenue growth from existing hospitals to continue until new hospitals are commissioned, barring major adverse events.
- Efforts will continue to sustain the margin expansion seen in the last two quarters, though no specific guidance is given.
- From Q4 onwards, focus will be on improving underwriting performance and optimizing the book rather than aggressive growth.
- Management expects the UK acquisition to be EPS neutral to mildly positive for the group, excluding one-time deal costs.
Risks flagged
- New hospitals coming up in these regions may pressure occupancy and realizations, especially in Gurgaon where competition is already intense.
- Large claims can cause quarterly swings in insurance losses; management acknowledged unpredictability quarter-on-quarter.
- While early results are expected soon, full realization of operational efficiencies and payer mix improvement may take longer, with no specific timeline given.
- Conscious volume reduction in scheme patients due to reimbursement caps and increased competition has led to slower growth in the North cluster.
Key quotes
- We have been a bit cognizant on the receivable problems in some of the scheme payers and also on the capping on reimbursement of certain drugs which has actually resulted in a conscious call in controlling volumes on the schemes.
- Our view on Gurgaon Delhi Hospital profitability aspects and ability to fill the beds from a competition viewpoint giving multiple large players are expanding already and have an existing presence. That has been our biggest challenge.
- We do believe that the UK acquisition will deliver reasonably strong ROCEs for us. It's a leveraged buyout, it's an asset-light model.
Research modules